PeptidePedia The community reference

Global access disparity: difference between revisions

Diff·revision 9 → 10·21:19, 21 Apr 2025

Difference between revision 9 and revision 10 of Global access disparity. 6 lines changed; the page grew by 581 bytes.

Revision 9 — 05:38, 2 Apr 2025
Chromatokid (talk)
attribute the survey figure to the survey and give its sample size
2,619 bytes ±0
Revision 10 — 21:19, 21 Apr 2025
AppealsArno (talk)
fix the anchor on an internal link
3,200 bytes +581
1{{Infobox concept1{{Infobox concept
2| name = Global access disparity2| name = Global access disparity
+3| subtitle = Health equity
3| Drivers = Price, manufacturing capacity, regulatory approval, coverage4| Drivers = Price, manufacturing capacity, regulatory approval, coverage
4| Consequence = Availability tracks income between and within countries5| Consequence = Availability tracks income between and within countries
1718
18Capacity expansion has been substantial since, and the constraint has eased in some markets. Whether that translates into broader availability depends on price and approval rather than on capacity alone.{{r|ada2024}}19Capacity expansion has been substantial since, and the constraint has eased in some markets. Whether that translates into broader availability depends on price and approval rather than on capacity alone.{{r|ada2024}}
+20
+21== Approval and coverage ==
+22A product cannot be sold where it is not approved, and applications are filed where a market is expected. Approval therefore follows commercial assessment as much as need. See [[Regulatory status by jurisdiction]].{{r|ada2024}}
+23
+24Where approved, coverage decisions determine affordability. Weight-management indications are covered less often than glycaemic ones in many systems, and out-of-pocket cost at list price exceeds what most households can sustain for a chronic therapy. See [[Cost per milligram]].{{r|kyle2021}}
1925
20== References ==26== References ==